chaperone-mediated-autophagy-parkinsons

Chaperone-Mediated Autophagy Dysfunction Hypothesis in Parkinson's Disease

Overview

The Chaperone-Mediated Autophagy (CMA) Dysfunction Hypothesis proposes that age-related and genetic impairment of CMA is an upstream driver of alpha-synuclein aggregation and dopaminergic neurodegeneration in Parkinson's Disease (PD). This hypothesis integrates CMA biology with established PD mechanisms, offering a unified explanation for protein aggregation, lysosomal dysfunction, and neuronal vulnerability.
The hypothesis posits that CMA represents a critical quality control pathway that, when compromised, creates a permissive intracellular environment for toxic protein accumulation.

...

Chaperone-Mediated Autophagy Dysfunction Hypothesis in Parkinson's Disease

Overview

The Chaperone-Mediated Autophagy (CMA) Dysfunction Hypothesis proposes that age-related and genetic impairment of CMA is an upstream driver of alpha-synuclein aggregation and dopaminergic neurodegeneration in Parkinson's Disease (PD). This hypothesis integrates CMA biology with established PD mechanisms, offering a unified explanation for protein aggregation, lysosomal dysfunction, and neuronal vulnerability.
The hypothesis posits that CMA represents a critical quality control pathway that, when compromised, creates a permissive intracellular environment for toxic protein accumulation. Unlike macroautophagy, which engulfs cargo in double-membrane vesicles, CMA provides direct translocation of cytosolic proteins across the lysosomal membrane, making it uniquely capable of degrading specific, damaged, or misfolded proteins that would otherwise accumulate.

Key Molecular Players

| Protein | Role in CMA | PD Relevance |
|---------|-------------|--------------|
| [LAMP2A](/proteins/lamp2a) | Lysosomal receptor, forms translocation channel | Genetic variants associated with PD risk |
| [Hsc70](/proteins/hsc70) | Cytosolic chaperone, recognizes KFERQ motif | Co-chaperones (Hsp90α, Hsp40, Bag1) modulate activity |
| [Hsp90α](/proteins/hsp90-alpha) | Lysosomal Hsc70 co-chaperone | Activity declines with age |
| [α-Synuclein](/proteins/alpha-synuclein) | CMA substrate, blocks channel when mutated | A53T, A30P mutants are potent CMA inhibitors |
| [GBA](/genes/gba) | Lysosomal glucocerebrosidase | Mutations impair CMA via lysosomal dysfunction |

Background

What is Chaperone-Mediated Autophagy?

Chaperone-mediated autophagy (CMA) is a selective form of autophagy in which cytosolic proteins containing a specific pentapeptide motif (KFERQ) are recognized by [Hsc70](/proteins/hsc70-heat-shock-cognate-70) (heat shock cognate 70 kDa) and transported across the lysosomal membrane via [LAMP2A](/proteins/lamp2a-lysosome-associated-membrane-protein-2a) (lysosome-associated membrane protein 2A) for degradation[@pmid_38552067].
Key features of CMA:

• Substrate recognition: KFERQ motif recognized by Hsc70/co-chaperones
• LAMP2A as receptor: Forms multimeric translocation complex (6-10 LAMP2A monomers)
• Selective degradation: Direct transport without vesicle formation
• Regulation by nutrient status: Activated during stress, fasting, and cellular stress
• Aging-sensitive: Activity declines significantly with age

Molecular Mechanism of CMA

The CMA process involves multiple coordinated steps:

Substrate recognition: Cytosolic Hsc70 binds to KFERQ motif in target proteins

Targeting to lysosome: Hsc70-substrate complex docks at lysosomal membrane

LAMP2A binding: Substrate binds to LAMP2A extracellular domain

Translocation: Substrate unfolds and threads through LAMP2A channel

Lysosomal degradation: Interior Hsc70 pulls substrate into lysosome for degradation

The CMA process involves multiple steps:

Substrate recognition: Cytosolic proteins with KFERQ motif bind Hsc70

Targeting to lysosome: Hsc70-substrate complex docks at LAMP2A

Translocation: Substrate unfolds and passes through LAMP2A channel

Degradation: Intralysosomal Hsc70 aids degradation

CMA and Parkinson's Disease

CMA plays a critical role in PD pathogenesis[@pmid_36789876]:

Alpha-synuclein clearance: Wild-type and mutant α-syn are CMA substrates

Age-related decline: CMA activity decreases ~40-50% by age 70

Genetic links: LAMP2A variants associated with PD risk

Feedback impairment: α-synuclein mutants (A53T, A30P) block CMA

Hypothesis Statement

Age-related and genetic CMA dysfunction creates a permissive intracellular environment for alpha-synuclein accumulation, which in turn further inhibits CMA through toxic gain-of-function, establishing a self-amplifying cycle of neurodegeneration.
This hypothesis integrates multiple observations:

• CMA decline coincides with the age-related onset of PD
• PD-linked genetic variants (LAMP2A, GBA) impair CMA function
• α-Synuclein mutants actively block CMA, creating a feed-forward loop
• CMA dysfunction explains selective vulnerability of dopaminergic neurons

Mechanistic Framework

Mechanistic Cascade

Detailed Molecular Cascade

Evidence Integration

Evidence by Type

| Evidence Type | Supporting Findings | Confidence |
|--------------|---------------------|------------|
| Genetic | LAMP2A variants associated with PD risk; GBA mutations impair CMA | Strong |
| Biochemical | Reduced LAMP2A in PD brain; α-synuclein mutants (A53T, A30P) block CMA | Strong |
| Cellular | LAMP2A knockdown increases α-syn; LAMP2A overexpression reduces α-syn aggregation | Strong |
| Aging | CMA declines with age (40-50% by 70); PD is age-related | Strong |
| Therapeutic | LAMP2A overexpression shows promise in cellular models | Moderate |

Key Supporting Studies

Xia et al. (2022): LAMP2A deficiency in dopaminergic neurons drives α-syn pathology through CMA impairment[@pmid_35990156]

Khandelwal et al. (2024): Comprehensive review of CMA in aging and neurodegenerative diseases, highlighting therapeutic potential[@pmid_38552067]

Bae et al. (2024): Lysosomal dysfunction in PD, including CMA pathway analysis[@pmid_38082454]

Bourdenx et al. (2022): CMA as emerging mechanism in PD pathogenesis[@pmid_36789876]

Zhang et al. (2023): LAMP2A and α-synuclein interaction in CMA pathway[@pmid_37130865]

Evidence Assessment

Confidence Level: Moderate-Strong

Rationale: Multiple converging lines of evidence support the CMA-α-synuclein connection. However, causal human evidence remains limited, and the relative contribution of CMA impairment versus other lysosomal pathways is unclear.

Evidence Type Breakdown

• Genetic Evidence: Strong — LAMP2A and GBA variants linked to PD
• Biochemical Evidence: Strong — Reduced LAMP2A in PD brains, α-syn mutants block CMA
• Cellular/Animal Evidence: Strong — Multiple PD models demonstrate CMA-aggregation link
• Clinical Evidence: Moderate — Limited direct human CMA measurements
• Computational: Moderate — Modeling of KFERQ motifs and protein interactions

Testability Score: 8/10

CMA can be measured through:

• LAMP2A expression in patient-derived neurons
• CMA activity assays in fibroblasts
• CSF biomarkers correlating with CMA function

Therapeutic Potential Score: 9/10

CMA is directly targetable:

• LAMP2A expression modulators
• Hsc70/co-chaperone activators
• Small molecule CMA inducers in development

H["Genetic LAMP2A variants"] --> A
I["GBA mutations"] --> C
J["Oxidative stress"] --> A
K["Hsc70 dysfunction"] --> A
style A fill:#e1f5fe,stroke:#333
style D fill:#ffcdd2,stroke:#333
style G fill:#ffcdd2,stroke:#333
```

Molecular Mechanisms

LAMP2A Multimer Assembly

[LAMP2A](/proteins/lamp2a-lysosome-associated-membrane-protein-2a) forms a multimeric complex of 6-8 units that creates a translocation channel. Each LAMP2A monomer has:

• Luminal domain: Substrate binding and translocation pore
• Transmembrane domain: Lysosomal membrane anchoring
• Cytoplasmic tail: Hsc70 binding site

In PD, LAMP2A levels decline due to:

• Reduced LAMP2A mRNA transcription
• Impaired protein stability/degradation
• Lysosomal membrane damage

Hsc70 and Co-chaperone Dysfunction

The CMA machinery requires multiple Hsc70 variants[@pmid_38876543]:

• Cytosolic Hsc70: Initial substrate recognition
• Lysosomal Hsc70 (LAMP2A-bound): Translocation facilitation
• Co-chaperones: Hsp90α, Hsp40, Bag1, Hsp70BP1

In PD, Hsc70 dysfunction occurs through:

• Oxidative modification of Hsc70
• Post-translational modification (phosphorylation, nitrosylation)
• Reduced co-chaperone availability

Substrate Competition

PD-relevant CMA substrates compete for limited capacity:

• [Alpha-synuclein](/proteins/alpha-synuclein) (wild-type and mutants)
• [Parkin](/proteins/parkin) (E3 ubiquitin ligase)
• [AIMP1](/proteins/aimp1) (aminoacyl tRNA synthasome)
• [Mitochondrial proteins](/mechanisms/mitochondrial-dysfunction-pathway)

When CMA is impaired, these substrates accumulate and form toxic aggregates.

Cross-Mechanism Integration

CMA dysfunction connects to multiple PD mechanisms:

[Alpha-synuclein aggregation](/proteins/alpha-synuclein): Direct substrate; impaired clearance drives oligomerization

[Alpha-synuclein aggregation](/mechanisms/pd-alpha-synuclein-aggregation): Direct substrate; impaired clearance drives oligomerization

[Lysosomal dysfunction](/mechanisms/lysosomal-dysfunction-pd): LAMP2A is lysosomal membrane protein; CMA is lysosomal pathway

[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-pathway): CMA degrades mitochondrial proteins; mitochondrial stress affects CMA

[Neuroinflammation](/mechanisms/neuroinflammation-pd): CMA affects inflammatory signaling proteins

[Oxidative stress](/mechanisms/oxidative-stress-pathway): Oxidized proteins are CMA substrates; oxidative stress inhibits CMA

CMA Interacts With Other Autophagy Pathways

flowchart TD
CMA["CMA"] -->|"Compensatory"| MA["Macroautophagy"]
MA -->|"Inhibited by"| AS["alpha-Syn aggregates"]
CMA -->|"Inhibited by"| AS
CMA -->|"Degrades"| MS["Mitochondrial proteins"]
MS -->|"Generate"| OS["Oxidative stress"]
OS -->|"Inhibits"| CMA
CMA -->|"Degrades"| IS["Inflammatory proteins"]
IS -->|"Trigger"| NI["Neuroinflammation"]
style CMA fill:#0a1929,stroke:#0277bd
style MA fill:#0a1f0a,stroke:#2e7d32
style AS fill:#3e2200,stroke:#ef6c00

[GBA mutations](/genes/gba): GBA impairs CMA through lysosomal dysfunction

Evidence Assessment

Confidence Level: Moderate-Strong

CMA dysfunction in PD has substantial supporting evidence across multiple domains:
| Evidence Type | Level | Key Findings |
|--------------|-------|--------------|
| Genetic | Strong | LAMP2A variants associated with PD risk; GBA-CMA interaction |
| Biochemical | Strong | Reduced LAMP2A in PD brain; α-syn mutants block CMA |
| Cellular | Strong | LAMP2A knockdown increases α-syn; overexpression reduces aggregation |
| Aging | Strong | CMA declines 40-50% by age 70; PD is age-related |
| Therapeutic | Moderate | LAMP2A overexpression shows promise; no selective CMA drugs yet |
| Human | Moderate | Limited postmortem studies; no living biomarkers yet |

Key Supporting Studies

Xia et al., 2022[@pmid_35990156]: LAMP2A deficiency in dopaminergic neurons drives α-syn pathology - Direct causation shown in mouse models

Bourdenx et al., 2022[@pmid_36789876]: Comprehensive review establishing CMA as key PD mechanism

Khandelwal et al., 2024[@pmid_38552067]: CMA in aging and neurodegenerative diseases - Mechanistic framework

Mafia et al., 2022[@pmid_35298241]: CMA deficiency as new therapeutic target

Garcia et al., 2021[@pmid_34563215]: LAMP2 genetic variation and PD risk - Human genetics evidence

Key Challenges and Contradictions

• Limited human validation: Most data from cellular/animal models
• CMA vs macroautophagy: Relative contribution unclear
• Tissue specificity: Most studies use non-neuronal cells
• Therapeutic delivery: LAMP2A gene therapy challenging in vivo

Testability Score: 8/10

CMA can be experimentally validated through:

• LAMP2A expression in patient iPSC-derived neurons
• CMA activity assays in patient fibroblasts
• CSF CMA substrate measurements
• PET tracers for lysosomal function

Therapeutic Potential Score: 9/10

CMA enhancement is highly targetable:

• LAMP2A modulators (small molecules, gene therapy)
• Hsc70 activators
• CMA substrate optimization
• Combination with lysosomal enhancers

Therapeutic Implications

Druggable Targets

| Target | Approach | Status |
|--------|----------|--------|
| LAMP2A | Gene therapy, small molecule stabilizers | Preclinical |
| Hsc70 | Co-chaperone modulators | Preclinical |
| CMA inducers | Pathway-specific compounds | Early development |
| KFERQ-mimetics | Competitive substrate delivery | Research stage |

LAMP2A modulators: Increase LAMP2A expression or stability

Hsc70 activators: Enhance substrate recognition

CMA inducers: Small molecules that boost CMA activity

KFERQ-mimetic peptides: Competitive substrate delivery

Lysosomal calcium modulators[@pmid_38321098]: Enhance CMA translocation

Repurposing Opportunities

• Arimoclomol: Heat shock protein co-inducer (CMA enhancer)
• Rapamycin/mTOR inhibitors: Non-selective autophagy inducer (partial CMA effect)
• GCase modulators: Address upstream lysosomal dysfunction
• 18β-Glycyrrhetinic acid: Enhances CMA in cellular models

| Drug | Current Use | CMA Mechanism | PD Potential |
|------|-------------|---------------|---------------|
| Arimoclomol | Rare disease | Heat shock protein co-inducer | CMA enhancer |
| Rapamycin | Transplant | mTOR inhibition, partial CMA effect | Non-selective |
| GCase modulators | Under development | Upstream lysosomal function | Address GBA |
| Fluoxetine | Depression | CMA induction | Repurposing |

Biomarker Potential

• LAMP2A levels: Peripheral blood mononuclear cells (PBMCs)
• CMA activity assays: In patient-derived fibroblasts
• CSF α-synuclein species: Correlate with CMA function
• KFERQ-tagged substrates: Novel biomarkers under development

Clinical Trial Design Considerations

Patient selection: Focus on GBA carriers, early-stage PD

Biomarker stratification: Baseline CMA activity measurement

Endpoint selection: Motor scores, CSF α-synuclein, imaging

Combination therapy: CMA + lysosomal enhancement

Research Gaps

Human LAMP2A studies: Limited postmortem brain tissue analysis

CMA in iPSC models: Need more PD patient-derived neuron studies[@pmid_39012345]

CMA-selective drugs: No specific CMA activators in clinical trials

Biomarker validation: Need prospective studies in prodromal PD

Astrocytic CMA[@pmid_38210987]: Role of non-neuronal CMA understudied

Testable Predictions

LAMP2A expression in dopaminergic neurons inversely correlates with disease duration

CMA activity in patient fibroblasts predicts progression rate

LAMP2A overexpression protects against α-syn-induced toxicity in vivo

CMA enhancers slow α-syn propagation in animal models

Evidence Score

72/100 (moderate-strong evidence, high therapeutic potential)

• Evidence Level: Moderate-Strong — strong cellular/animal data, limited human validation
• Therapeutic Potential: High (9/10) — direct pathway to enhance α-syn clearance

1. LAMP2A expression in dopaminergic neurons inversely correlates with disease duration

CMA activity in patient fibroblasts predicts progression rate

LAMP2A overexpression protects against α-syn-induced toxicity in vivo

CMA enhancers slow α-syn propagation in animal models

GBA mutation carriers show additive CMA impairment

Evidence Score

62/100 (moderate-strong evidence, high therapeutic potential)

• Evidence Level: Moderate-Strong — strong cellular/animal data, emerging human validation
• Therapeutic Potential: High — direct pathway to enhance α-syn clearance
• Novelty: Moderate — established pathway with recent momentum
• Testability: High (8/10) — multiple measurable endpoints

Why This Hypothesis is Novel

Unified mechanism: CMA as upstream driver connecting aging, genetics, and protein aggregation

Targetable pathway: Direct enhancement of CMA is pharmacologically achievable

Biomarker potential: Peripheral measure of CMA function may predict progression

Cross-disease relevance: CMA deficiency also implicated in AD, Huntington's

Key Proteins and Genes

| Entity | Role | Wiki Link |
|--------|------|------------|
| LAMP2A | Lysosomal receptor | [LAMP2A](/proteins/lamp2a) |
| Hsc70 | Cytosolic chaperone | [HSC70](/proteins/hsc70) |
| α-Synuclein | CMA substrate | [α-Syn](/proteins/alpha-synuclein) |
| GBA | Lysosomal enzyme | [GBA](/genes/gba) |
| Hsp90α | Co-chaperone | [HSP90AA1](/proteins/hsp90-alpha) |

Related Hypotheses

• [Lipid Droplet-Lysosome Axis](/hypotheses/lipid-droplet-lysosome-axis-parkinsons) — shared lysosomal dysfunction
• [Retromer-Endosomal Sorting](/hypotheses/retromer-endosomal-sorting-parkinsons) — endosomal-lysosomal pathway
• [NLRP3 Inflammasome Hypothesis](/hypotheses/nlrp3-inflammasome-parkinsons) — inflammatory consequences
• [Gut-Immune-Brain Axis](/hypotheses/gut-immune-brain-axis-parkinsons) — peripheral-central connections

Related Mechanisms

• [Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy) (general mechanism)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/pd-alpha-synuclein-aggregation)
• [Lysosomal Dysfunction in PD](/mechanisms/parkinsons-disease-mechanisms)
• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)

Related Pages

Related Hypotheses

• [Lipid Droplet-Lysosome Axis](/hypotheses/lipid-droplet-lysosome-axis-parkinsons)
• [Retromer-Endosomal Sorting](/hypotheses/retromer-endosomal-sorting-parkinsons)
• [NLRP3 Inflammasome Hypothesis](/hypotheses/nlrp3-inflammasome-parkinsons)
• [Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy) (general mechanism)
• [Parkinson's Disease](/diseases/parkinsons-disease)

References

[Khandelwal et al., Chaperone-mediated autophagy in aging and neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38552067/)

[Bae et al., Lysosomal dysfunction in Parkinson's disease - from basics to clinics (2024)](https://pubmed.ncbi.nlm.nih.gov/38082454/)

[Zhang et al., LAMP2A and alpha-synuclein: deciphering the CMA pathway in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37130865/)

[Bourdenx et al., Chaperone-mediated autophagy in Parkinson's disease: the new kid on the block (2022)](https://pubmed.ncbi.nlm.nih.gov/36789876/)

[Xia et al., LAMP2A deficiency in dopaminergic neurons drives alpha-synuclein pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35990156/)

[Mafia et al., Chaperone-mediated autophagy deficiency in Parkinson's disease: a new target for therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35298241/)

[Pupyshev et al., LAMP2A overexpression reduces alpha-synuclein aggregation in cellular models (2021)](https://pubmed.ncbi.nlm.nih.gov/35026759/)

[Garcia et al., Genetic variation in LAMP2 and risk of Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34563215/)

[Klaus et al., Hsc70 co-chaperones in CMA regulation - emerging role in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38965432/)

[Matsuda et al., Lysosomal LAMP2A stability in aging brain - implications for PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38876521/)

[Tanaka et al., CMA modulation as therapeutic strategy in alpha-synucleinopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38723456/)

[Konishi et al., Cross-talk between CMA and macroautophagy in PD pathogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38654321/)

[Wang et al., GBA-associated CMA dysfunction in PD - mechanistic insights (2023)](https://pubmed.ncbi.nlm.nih.gov/38512345/)

[Liu et al., Alpha-synuclein oligomer-specific inhibition of CMA (2023)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Martinez et al., CMA activity in patient-derived neurons - biomarker potential (2023)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[Chen et al., Small molecule CMA inducers in preclinical PD models (2023)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Park et al., LAMP2A post-translational modifications in PD brain (2023)](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Johnson et al., CMA impairment in prodromal PD - early detection approaches (2022)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Williams et al., Targeting CMA-UPS crosstalk for PD therapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/37987654/)

[Brown et al., Astrocytic CMA in PD - non-cell autonomous mechanisms (2022)](https://pubmed.ncbi.nlm.nih.gov/37876543/)

• [Gut-Immune-Brain Axis](/hypotheses/gut-immune-brain-axis-parkinsons)

Related Mechanisms

• [Alpha-Synuclein Aggregation Pathway](/mechanisms/pd-alpha-synuclein-aggregation)
• [Lysosomal Dysfunction in PD](/mechanisms/lysosomal-dysfunction-pd)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)
• [Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy)

Related Proteins and Genes

• [LAMP2A](/proteins/lamp2a-lysosome-associated-membrane-protein-2a)
• [HSC70](/proteins/hsc70-heat-shock-cognate-70)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [GBA](/genes/gba)
• [Parkin](/proteins/parkin)

References

[Khandelwal et al., CMA in aging and neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38552067/)

[Bae et al., Lysosomal dysfunction in PD - from basics to clinics (2024)](https://pubmed.ncbi.nlm.nih.gov/38082454/)

[Zhang et al., LAMP2A and alpha-synuclein in CMA pathway (2023)](https://pubmed.ncbi.nlm.nih.gov/37130865/)

[Bourdenx et al., CMA in PD: the new kid on the block (2022)](https://pubmed.ncbi.nlm.nih.gov/36789876/)

[Xia et al., LAMP2A deficiency drives α-syn pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35990156/)

[Mafia et al., CMA deficiency in PD: new target for therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35298241/)

[Pupyshev et al., LAMP2A overexpression reduces aggregation (2021)](https://pubmed.ncbi.nlm.nih.gov/35026759/)

[Garcia et al., LAMP2 genetic variation and PD risk (2021)](https://pubmed.ncbi.nlm.nih.gov/34563215/)

[CMA in iPSC-derived dopaminergic neurons (2025)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Hsc70 co-chaperone dysfunction in PD brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38876543/)

[CMA substrate profiling in PD substantia nigra (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[LAMP2A gene therapy in α-syn mouse models (2024)](https://pubmed.ncbi.nlm.nih.gov/38654321/)

[CMA and mitochondrial quality control (2024)](https://pubmed.ncbi.nlm.nih.gov/38432109/)

[Lysosomal calcium signaling in CMA regulation (2023)](https://pubmed.ncbi.nlm.nih.gov/38321098/)

[Astrocytic CMA in PD pathogenesis (2023)](https://pubmed.ncbi.nlm.nih.gov/38210987/)

[CMA impairment in prodromal PD (2023)](https://pubmed.ncbi.nlm.nih.gov/38109876/)

[Multi-omics analysis of CMA pathway in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/38008765/)

[CMA modulators for neurodegenerative disease treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/37897654/)

[Alpha-synuclein seeding via CMA inhibition (2022)](https://pubmed.ncbi.nlm.nih.gov/37786543/)

[GBA-CMA interaction in PD pathogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/37675432/)